Literature DB >> 7830280

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.

G J Bridger1, R T Skerlj, D Thornton, S Padmanabhan, S A Martellucci, G W Henson, M J Abrams, N Yamamoto, K De Vreese, R Pauwels.   

Abstract

We have previously described the potent and selective inhibition of several strains of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) by JM2763, an n-propyl-linked dimer of the 1,4,8,11-tetraazamacrocyclic (cyclam) ring system. Upon further investigation, we have also found that incorporating an aromatic rather than aliphatic linker leads to analogs with higher antiviral potency. The prototype, JM3100 (19a, isolated as the octahydrochloride salt), which contains a p-phenylenebis(methylene) moiety linking the cyclam rings, inhibited the replication of HIV-1 (IIIB) and HIV-2 (ROD) at EC50's of 4.2 and 5.9 nM, respectively, while remaining nontoxic to MT-4 cells at concentrations exceeding 421 microM. In order to identify the structural features of bis-tetraazamacrocycles required for potent activity, we have prepared a novel series of phenylenebis(methylene)-linked analogs, in which the macrocyclic ring size was varied from 12 to 16 ring members. Depending upon the substitution of the phenylenebis(methylene) linker (para or meta), sub-micromolar anti-HIV activity was exhibited by analogs bearing macrocycles of 12-14 ring members but with varying cytotoxicity to MT-4 cells. Furthermore, while we found that identical macrocyclic rings are not required for activity, substituting an acyclic polyamine equivalent for one of the cyclam rings in 19a resulted in a substantial reduction in anti-HIV potency, clearly establishing the importance of the constrained macrocyclic structure. A short series of transition metal complexes of 19a were also prepared and evaluated. Complexes of low kinetic stability such as the bis-zinc complex retained activity comparable to that of the parent compound. Finally, the activity of bicyclam analogs appears to be insensitive to the electron-withdrawing or -donating properties of substituents introduced onto the linker, but sterically hindering groups such as phenyl markedly reduced activity. As a result, several analogs with anti-HIV potency comparable to that of 19a have been identified.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7830280     DOI: 10.1021/jm00002a019

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  45 in total

1.  Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma.

Authors:  Brian R Lane; Jianguo Liu; Paul J Bock; Dominique Schols; Michael J Coffey; Robert M Strieter; Peter J Polverini; David M Markovitz
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes.

Authors:  Evelyne Schaeffer; Vanessa B Soros; Warner C Greene
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope.

Authors:  Eric G Meissner; Karen M Duus; Feng Gao; Xiao-Fang Yu; Lishan Su
Journal:  Virology       Date:  2004-10-10       Impact factor: 3.616

4.  Characterization of primary isolates of HIV type 1 CRF28_BF, CRF29_BF, and unique BF recombinants circulating in São Paulo, Brazil.

Authors:  Fernando Lucas Melo; Leda Fátima Jamal; Paolo Marinho de Andrade Zanotto
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-16       Impact factor: 2.205

5.  Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.

Authors:  Guity Ghaffari; Daniel L Tuttle; Daniel Briggs; Brant R Burkhardt; Deepa Bhatt; Warren A Andiman; John W Sleasman; Maureen M Goodenow
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation.

Authors:  Jerry S Hu; Christine M Freeman; Valerie R Stolberg; Bo Chin Chiu; Gary J Bridger; Simon P Fricker; Nicholas W Lukacs; Stephen W Chensue
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 7.  Physiology and pharmacology of plerixafor.

Authors:  Simon P Fricker
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

8.  Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor.

Authors:  Aymeric de Parseval; Udayan Chatterji; Peiqing Sun; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

9.  64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

Authors:  Orit Jacobson; Ido D Weiss; Lawrence Szajek; Joshua M Farber; Dale O Kiesewetter
Journal:  Bioorg Med Chem       Date:  2009-01-15       Impact factor: 3.641

10.  Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors.

Authors:  Beatriz Pacheco; Stephane Basmaciogullari; Jason A Labonte; Shi-Hua Xiang; Joseph Sodroski
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.